Leerink Partnrs Estimates Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the company will earn $0.43 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. Leerink Partnrs also issued estimates for Genmab A/S’s FY2025 earnings at $1.59 EPS and FY2026 earnings at $1.99 EPS.

Several other research firms also recently commented on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $21.77 on Monday. The stock has a fifty day simple moving average of $20.64 and a two-hundred day simple moving average of $23.02. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.88. The firm has a market capitalization of $14.41 billion, a PE ratio of 21.14, a PEG ratio of 0.54 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%.

Institutional Trading of Genmab A/S

Several institutional investors have recently added to or reduced their stakes in the company. Deep Track Capital LP bought a new stake in Genmab A/S in the fourth quarter worth about $41,740,000. Renaissance Technologies LLC lifted its stake in Genmab A/S by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after purchasing an additional 139,722 shares during the last quarter. Two Sigma Investments LP lifted its stake in Genmab A/S by 122.2% in the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Two Sigma Advisers LP lifted its stake in Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after purchasing an additional 1,038,400 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in Genmab A/S by 18.0% in the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock worth $34,316,000 after purchasing an additional 251,241 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.